Arca Biopharma Inc Quick Ratio (ABIO) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Arca Biopharma Inc  (NASDAQ: ABIO)

Arca Biopharma Inc's Quick Ratio

ABIO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Arca Biopharma Inc's Cash & cash equivalent grew by 472.38 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Arca Biopharma Inc's Quick Ratio to 87.05 a new company high.

Within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Arca Biopharma Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 43, from total ranking in the first quarter 2026 at 124.

Explain Quick Ratio?
How much Cash & cash equivalents ABIO´s has?
What are ABIO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ABIO Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 111.11 % 41.88 % 51.96 % 16.23 % 852.79 %
Y / Y Cash & cash equivalent Change 577.69 % 11.38 % -57.2 % -15.02 % 886.71 %
Quick Ratio MRQ 87.05 23.38 21.92 16.65 27.12
ABIO's Total Ranking # 43 # 124 # 93 # 110 # 78
Seq. Current Liabilities Change 53.71 % 8.19 % -26.68 % 73.14 % 3.3 %
Seq. Cash & cash equivalent Change 472.38 % 15.36 % -3.47 % 6.32 % -5.93 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 5
Overall Market # 43


Quick Ratio Statistics
High Average Low
87.05 19.65 4.27
(Jun 30 2026)   (Mar 31 2013)




Financial Statements
Arca Biopharma Inc's Current Liabilities $ 26 Millions Visit ABIO's Balance sheet
Arca Biopharma Inc's Cash & cash equivalent $ 2,226 Millions Visit ABIO's Balance sheet
Source of ABIO's Sales Visit ABIO's Sales by Geography


Cumulative Arca Biopharma Inc's Quick Ratio

ABIO's Quick Ratio for the trailling 12 Months

ABIO Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 51.07 % 58.16 % 94.06 % 155.1 % 1060.21 %
Y / Y Cash & cash equivalent TTM Growth 75.96 % -11.21 % 7.59 % 250.55 % 1192.72 %
Quick Ratio TTM 42.02 21.56 22.66 33.03 36.08
Total Ranking TTM # 2211 # 2208 # 1809 # 1453 # 1929
Seq. Current Liabilities TTM Growth 20.67 % 8.16 % 9.57 % 5.63 % 26.34 %
Seq. Cash & cash equivalent TTM Growth 135.18 % 2.91 % -24.83 % -3.29 % 18.67 %

Quick ratio ranking by company, industry and sector >> Back to ABIO Financial Strength Comparisons >> Go to Compare ABIO Quick Ratio to its Competitors

On the trailing twelve months basis ABIO Cash & cash equivalent more than doubled by 577.69 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Arca Biopharma Inc's Quick Ratio to 42.02, above ABIO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 378 other companies have achieved higher Quick Ratio than Arca Biopharma Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2208 to 2211.

Explain Quick Ratio?
How much Cash & cash equivalents ABIO´s has?
What are ABIO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 379
Healthcare Sector # 718
Within the Market # 2211


trailing twelve months Quick Ratio Statistics
High Average Low
43.46 18.33 6.3
(Jun 30 2026)   (Mar 31 2018)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Mira Pharmaceuticals Inc   198.75 $ 8.113  Millions$ 0.041  Millions
Veradermics Inc  139.85 $ 1,635.362  Millions$ 11.694  Millions
Enliven Therapeutics Inc   116.86 $ 1,654.850  Millions$ 14.161  Millions
Acrivon Therapeutics Inc   104.48 $ 89.959  Millions$ 0.861  Millions
Arca Biopharma Inc  87.05 $ 2,225.581  Millions$ 25.566  Millions
Tango Therapeutics Inc   82.19 $ 1,668.432  Millions$ 20.299  Millions
Contineum Therapeutics Inc   70.25 $ 458.440  Millions$ 6.526  Millions
Sagimet Biosciences inc   61.23 $ 331.832  Millions$ 5.419  Millions
Avalyn Pharma Inc   49.93 $ 539.733  Millions$ 10.809  Millions
Pasithea Therapeutics Corp   49.76 $ 91.464  Millions$ 1.838  Millions
Disc Medicine Inc   44.03 $ 1,336.770  Millions$ 30.360  Millions
Trevi Therapeutics Inc   36.50 $ 318.870  Millions$ 8.736  Millions
Design Therapeutics Inc   35.76 $ 401.889  Millions$ 11.240  Millions
Mineralys Therapeutics Inc   34.87 $ 673.704  Millions$ 19.319  Millions
Praxis Precision Medicines Inc   34.32 $ 1,683.790  Millions$ 49.058  Millions
Agios Pharmaceuticals Inc   33.94 $ 2,383.112  Millions$ 70.217  Millions
Mbx Biosciences Inc   33.10 $ 783.099  Millions$ 23.660  Millions
Xbiotech Inc   32.67 $ 109.528  Millions$ 3.353  Millions
Avalo Therapeutics Inc   31.89 $ 787.143  Millions$ 24.682  Millions
Fulcrum Therapeutics Inc   30.96 $ 318.840  Millions$ 10.298  Millions
Climb Bio Inc   30.86 $ 183.123  Millions$ 5.934  Millions
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions

Date modified: 2026-08-12T19:31:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.